Soleo Health, a prominent provider of specialized pharmacy services for rare and ultra-rare diseases, has been designated as a limited distribution specialty pharmacy partner for dispensing RYPLAZIM® (plasminogen, human-tvmh), developed…
GlycoMimetics, Inc. (Nasdaq: GLYC), a biotechnology company specializing in advanced therapies for cancer and inflammatory conditions, has released the top-line results from its Phase 3 global pivotal trial of uproleselan…
Lantern Pharma Inc. (NASDAQ: LTRN), a prominent player in artificial intelligence (AI)-driven oncology drug discovery and development, has announced a strategic partnership with Oregon Therapeutics, a distinguished French biotechnology company.…
Kindeva Drug Delivery, a prominent figure in the realm of drug-device combination products, has unveiled its plans to bolster its manufacturing capabilities with a second production line for pressurized metered-dose…
UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from a sub-analysis within the largest real-world patient cohort evaluation of JELMYTO (mitomycin) for pyelocalyceal solution, presented at the American Urological…
GE HealthCare (Nasdaq: GEHC) has introduced SIGNA MAGNUS, a head-only magnetic resonance (MR) scanner awaiting FDA 510(k) approval. This cutting-edge technology aims to revolutionize neuroscience research, addressing the limitations of…
The U.S. Food and Drug Administration (U.S. FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) aimed at treating adult patients with relapsed or…
Astellas Pharma Inc. (TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have announced a strategic collaboration between Astellas’ subsidiary Xyphos Biosciences, Inc. and Poseida. The agreement aims to develop innovative…
Teacher Appreciation Week arrives annually during the first full week of May, serving as a dedicated time to recognize and celebrate the unwavering commitment of educators worldwide. It presents an…
Summary of Financial Highlights: In the first quarter of 2024, the company experienced significant growth across various metrics: Overall, the company demonstrated robust growth in revenues and product sales, despite…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced its financial results for the first quarter ending March 31, 2024, along with notable recent business achievements. Yvonne…
Moderna, Inc. (NASDAQ: MRNA) has released its financial results for the first quarter of 2024, along with key updates on its business operations. Stéphane Bancel, the Chief Executive Officer of…